Market Overview

UPDATE: Stifel Nicolaus Initiates Infinity Pharmaceuticals at Hold; Royalty Burden High

Related INFI
25 Stocks Which Rallied Four Days, Then Sold Off Yesterday
The Biggest Pharma Stock Blowups Of 2016

Stifel Nicolaus initiated coverage on Infinity Pharmaceuticals (NASDAQ: INFI) with a Hold rating.

Stifel Nicolaus noted, "Infinity's phosphoinositide-3-kinase (PI3K) inhibitor, IPI-145, has the potential to be a best-in-class drug for one of the most exciting targets in oncology and inflammation treatment. Preclinical data for IPI-145 as well as data from other drugs in development validate the PI3K target in our opinion as one that will provide strong efficacy in tumor resistance and inflammation reduction, while retaining a favorable safety profile. IPI-145 is the only dual PI3K delta and gamma inhibitor currently in clinical trials."

Infinity Pharmaceuticals closed at $17.74 on Thursday.

Latest Ratings for INFI

Jun 2016William BlairDowngradesOutperformMarket Perform
Jun 2016Wells FargoDowngradesOutperformMarket Perform
Jun 2016JefferiesDowngradesBuyHold

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (INFI)

View Comments and Join the Discussion!